

# M59

## Epidemiological Cutoff Values for Antifungal Susceptibility Testing

This document provides epidemiological cutoff values developed according to the criteria in the Clinical and Laboratory Standards Institute (CLSI) guideline M57 and generated according to the reference broth dilution methods described in the CLSI standards M27 and M38.

A CLSI supplement for global application.

# Clinical and Laboratory Standards Institute

*Setting the standard for quality in medical laboratory testing around the world.*

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing medical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

## Consensus Process

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

## Commenting on Documents

CLSI documents undergo periodic evaluation and modification to keep pace with advances in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI's consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential and may be submitted by anyone, at any time, on any document. All comments are managed according to the consensus process by a committee of experts.

## Appeal Process

When it is believed that an objection has not been adequately considered and responded to, the process for appeal, documented in the CLSI *Standards Development Policies and Processes*, is followed.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

## Get Involved—Volunteer!

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For additional information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute  
950 West Valley Road, Suite 2500  
Wayne, PA 19087 USA  
P: +1.610.688.0100  
F: +1.610.688.0700  
[www.clsi.org](http://www.clsi.org)  
[standard@cls.org](mailto:standard@cls.org)

This is a preview. [Click here to purchase the full publication.](#)

---

## Epidemiological Cutoff Values for Antifungal Susceptibility Testing

Gary W. Procop, MD, MS  
Philippe J. Dufresne, PhD, RMCCM  
Elizabeth Berkow, PhD  
Mariana Castanheira, PhD  
Jeff Fuller, PhD, FCCM, D(ABMM)  
Kimberly E. Hanson, MD, MHS  
Nicole M. Holliday, BA

David H. Pincus, MS, RM/SM(NRCM),  
SM(ASCP)  
Audrey N. Schuetz, MD, MPH, D(ABMM)  
Paul E. Verweij, MD, FECMM  
Nathan P. Wiederhold, PharmD  
Adrian M. Zelazny, PhD, D(ABMM)

### Abstract

Clinical and Laboratory Standards Institute document M59—*Epidemiological Cutoff Values for Antifungal Susceptibility Testing* includes epidemiological cutoff values (ECVs) and quality control tables developed following the guidance in CLSI document M57.<sup>1</sup> These ECVs are valid only when they are developed in accordance with CLSI document M57<sup>1</sup> and when minimal inhibitory concentrations or minimal effective concentrations are generated according to the reference broth dilution methods described in CLSI documents M27<sup>2</sup> and M38.<sup>3</sup> Users should replace previously published tables with these new tables. Changes in the tables since the previous edition appear in boldface type.

Clinical and Laboratory Standards Institute (CLSI). *Epidemiological Cutoff Values for Antifungal Susceptibility Testing*. 3rd ed. CLSI supplement M59 (ISBN 978-1-68440-080-5 [Print]; ISBN 978-1-68440-081-2 [Electronic]). Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA, 2020.

The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at [www.clsi.org](http://www.clsi.org). If you or your organization is not a member and would like to become one, or to request a copy of the catalog, contact us at: Telephone: +1.610.688.0100; Fax: +1.610.688.0700; E-Mail: [customerservice@cls.org](mailto:customerservice@cls.org); Website: [www.clsi.org](http://www.clsi.org).



**CLINICAL AND  
LABORATORY  
STANDARDS  
INSTITUTE®**

This is a preview. [Click here to purchase the full publication.](#)

Copyright ©2020 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of content from a CLSI copyrighted standard, guideline, companion product, or other material requires express written consent from CLSI. All rights reserved. Interested parties may send permission requests to [permissions@clsi.org](mailto:permissions@clsi.org).

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedures manual at a single site. To request permission to use this publication in any other manner, e-mail [permissions@clsi.org](mailto:permissions@clsi.org).

### **Suggested Citation**

CLSI. *Epidemiological Cutoff Values for Antifungal Susceptibility Testing*. 3rd ed. CLSI supplement M59. Wayne, PA: Clinical and Laboratory Standards Institute; 2020.

### **Previous Editions:**

April 2016, January 2018

M59-Ed3

ISBN 978-1-68440-080-5 (Print)

ISBN 978-1-68440-081-2 (Electronic)

ISSN 1558-6502 (Print)

ISSN 2162-2914 (Electronic)

Volume 40, Number 7

## Committee Membership

### Subcommittee on Antifungal Susceptibility Tests

**Gary W. Procop, MD, MS**  
Chairholder  
Cleveland Clinic  
USA

**Philippe J. Dufresne, PhD, RMCCM**  
Vice-Chairholder  
Institut national de santé publique du Québec  
Canada

**Camille Hamula, PhD, D(ABMM)**  
Committee Secretary  
Saskatoon Health Region/University of Saskatchewan  
Canada

Elizabeth Berkow, PhD  
Centers for Disease Control and Prevention  
USA

Jeff Fuller, PhD, FCCM, D(ABMM)  
London Health Sciences Centre  
Canada

Kimberly E. Hanson, MD, MHS  
University of Utah and ARUP Laboratories  
USA

Nicole M. Holliday, BA  
Thermo Fisher Scientific  
USA

David H. Pincus, MS, RM/SM(NRCM), SM(ASCP)  
bioMérieux, Inc.  
USA

Audrey N. Schuetz, MD, MPH, D(ABMM)  
Mayo Clinic  
USA

Paul E. Verweij, MD, FECMM  
Radboud University Medical Center  
Netherlands

Nathan P. Wiederhold, PharmD  
University of Texas Health Science Center at San Antonio  
USA

Adrian M. Zelazny, PhD, D(ABMM)  
USA

### Working Group on Antifungal Epidemiological Cutoff Values

**Shawn R. Lockhart, PhD, D(ABMM), F(AAM)**  
Chairholder  
Centers for Disease Control and Prevention  
USA

**Philippe J. Dufresne, PhD, RMCCM**  
Vice-Chairholder  
Institut national de santé publique du Québec  
Canada

**Nathan P. Wiederhold, PharmD**  
Committee Secretary  
University of Texas Health Science Center at San Antonio  
USA

Barbara D. Alexander, MD, MHS  
Duke University Medical Center  
USA

Elizabeth Berkow, PhD  
Centers for Disease Control and Prevention  
USA

Jeff Fuller, PhD, FCCM, D(ABMM)  
London Health Sciences Centre  
Canada

Mahmoud A. Ghannoum, PhD, FIDSA, MBA  
Case Western Reserve University  
USA

Kerian K. Grande Roche, PhD  
FDA Center for Drug Evaluation and Research  
USA

Kimberly E. Hanson, MD, MHS  
University of Utah and ARUP Laboratories  
USA

John D. Turnidge, MD, BS, FRACP, FASM, FRCPA  
The University of Adelaide  
Australia

Thomas J. Walsh, MD, FIDSA, FAAM, FECMM  
Weill Cornell Medicine of Cornell University and New York Presbyterian Hospital  
USA